Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
Combination anticancer therapy is promising to generate synergistic anticancer effects, to maximize the treatment effect and to overcome multi-drug resistance. Nanostructured lipid carriers (NLCs), composed of solid and liquid lipids, and surfactants are potentially good colloidal drug carriers. The aim of this study is to construct a hyaluronic acid (HA) decorated NLCs as nanocarriers for co-delivery baicalein (BCL) and doxorubicin (DOX). BCL- and DOX-loaded NLCs (BCL/DOX-NLCs) were prepared. HA ligands were used for the decoration of BCL/DOX-NLCs to form HA decorated BCL/DOX-NLCs (HA-BCL/DOX-NLCs). The in vitro cytotoxicity studies of different formulations were evaluated on DOX drug-resistant MCF-7 breast cancer cell line (MCF-7/ADR cells). In vivo anti-tumor effects were observed on the murine bearing MCF-7/ADR cells model. HA-BCL/DOX-NLCs showed highest cytotoxicity and synergistic effect of two drugs in tumor cells in vitro. The in vivo study revealed the greatest anti-tumor activity than all the other formulations in the murine breast cancer model. HA decorated NLCs could be used as a novel carrier to co-delivery BCL and DOX for breast cancer therapy. HA-BCL/DOX-NLCs could be a promising targeted and combinational therapy nanomedicine.